Sign In
Buy GLP
$48.46
-0.170 (-0.350%)
At Close: Jul 29, 2026
Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles
01:21pm, Wednesday, 06'th Aug 2025
NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.
Hims & Hers: GLP-1 Strategy Is On Dubious Grounds
01:00pm, Wednesday, 06'th Aug 2025
Hims & Hers Health showed a sharper-than-expected revenue hiccup in Q2, sending the stock down. The results reflect GLP-1 concerns. Hims & Hers' GLP-1 strategy is now on dubious grounds after Novo Nor
There Is Only 1 GLP-1 Stock to Buy In 2025
11:35am, Wednesday, 06'th Aug 2025
Key Points in This Article: Ozempic's introduction shifted obesity treatment from lifestyle to pharmacological solutions, using GLP-1 drugs to regulate appetite and glucose.
GLP-1 "Arms Race" Broadens to Include Dozens of Companies
09:20am, Wednesday, 06'th Aug 2025
Lexaria highlights DehydraTECH's adverse events improvement opportunity KELOWNA, BC / ACCESS Newswire / August 6, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria
Wait Out The GLP-1 Storm - Buy The Hims And Hers Post-Earnings Dip
01:02pm, Tuesday, 05'th Aug 2025
Hims and Hers faced a short-term revenue dip due to regulatory changes and GLP-1 customer offboarding, but core growth remains strong. Subscriber numbers surged 31% quarter-over-quarter, and product d
Inspire Medical Systems Crashes 32% As Eli Lilly's GLP-1 Weighs On Guidance
09:30am, Tuesday, 05'th Aug 2025
Inspire Medical Systems crashed Tuesday after the maker of implantable sleep apnea devices called out GLP-1 drugs for weighing on sales.
GLP-1 War: A Look At The Epic Pipeline Battle Between Novo Nordisk And Eli Lilly
09:09am, Tuesday, 05'th Aug 2025
Novo Nordisk's share price collapse is an overreaction; the market underestimates its robust pipeline and continued double-digit growth potential. The GLP-1 obesity drug market is massive and supports
Will GLP-1 Demand Drive MCK's Top Line This Earnings Season?
08:41am, Tuesday, 05'th Aug 2025
MCK's Q1 results are expected to reflect strong prescription volume growth from GLP-1 demand, but lower margins may weigh on profitability.
Hims & Hers: Buy The Core Engine, Not The Headline
08:15am, Tuesday, 05'th Aug 2025
Hims & Hers Health's Q2 revenue miss and decelerating growth triggered a stock drop, but core business ex-GLP-1 remains robust with strong subscriber growth. Profitability is improving, with adjusted
- 13-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of two oral formulations of ASC30, a once-daily tablet, in 125 participants with obesity or overwei
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
08:00pm, Monday, 04'th Aug 2025
SAN FRANCISCO and SUZHOU, China , Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercial
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
01:11pm, Monday, 04'th Aug 2025
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight In the trial, Mounjaro was associated
West Pharmaceutical: Q2 Earnings Suggest Recovery
12:20pm, Wednesday, 30'th Jul 2025
West Pharmaceutical Services, Inc.'s Q2 results signal a return to growth, driven by strong demand for high-value products and GLP-1 agonist components. I am revamping my bullish thesis: GLP-1 drugs n
Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?
09:00am, Wednesday, 30'th Jul 2025
The sharp Novo Nordisk A/S stock drop reflects real concerns: slowing demand, CEO transition, rising competition, and macro headwinds. GLP-1 hype is fading as insurance coverage wanes, compounded gene
